IRCT20200302046673N1已完成未知
Effect of oral miltefosin on treatment of chronic anthropological cutaneous leishmaniasis
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 years 至 no limit（—）
- 性别
- All
入选标准
- •Individuals with antroponotic leishmaniasis over two year who have not received remission despite two courses of systemic glucontime or one cours of systemic glugantime plus one course of intraleasional injection
排除标准
- •Children Under Two Year
- •Pregnancy and Lactation
- •Renal Disorer
- •Liver Disorder
- •Heart Disease
研究者
相似试验
尚未招募
3 期
Comparison of the effect and toxicity between two options for the treatment of Mucosal Leishmaniasis: Miltefosin and Liposomal Anfotericin BRBR-5r93wnCentro de Pesquisa Rene Rachou, Fundação Oswaldo Cruz
进行中（未招募）
不适用
Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria - MIARCrticaria characterized by mast cell and histamine-dependent wheal and flair type-skin responses associated with severe pruritus. The disease is very common and not always easy to treat. Mainstay therapeutics are antihistamines, which show poor response rates (about 20%-50%) when used in standard dosage. The up-dosing of antihistamines to four-times daily dose does improve the response rate. However, a significant percentage of patients still do not reach sufficient symptom control.EUCTR2007-007657-31-DECharité-University Berlin
招募中
1 期
ong-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapiesnresectable stage III or IV melanoma, Relapsed or refractory CD19 positive B cell malignancies (adult ALL, adult NHL/chronic lymphatic leukemia [CLL]), Relapsed or refractory CD19 positive B cell malignancies (pediatric acute lymphatic leukemia [ALL], aggressive NHL), Relapsed or refractory CD20 positive B-cell non-Hodgkin’s lymphoma (NHL), Relapsed or refractory B cell non-Hodgkins lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code: 10063625Term: Acute lymphoblastic leukemia recurrent Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10003902Term: B-cell lymphoma recurrent Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027152Term: Melanoma of skin (malignant) Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008978Term: Chronic lymphocytic leukemia refractory Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008977Term: Chronic lymphocytic leukemia recurrent Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10003903Term: B-cell lymphoma refractory Class: 100000004864CTIS2022-501648-14-00Miltenyi Biomedicine GmbH40
招募中
3 期
oral melatonin in the treatment of acute respiratory distress syndromeIRCT20130308012743N3Mashhad University of Medical Sciences74
进行中（未招募）
不适用
Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis - MICUMAchronic stable symptomatic maculopapulous cutaneous mastocytosis or systemic mastocytosis with involvement of the skin and with positive Darier´s signMedDRA version: 9.1Level: LLTClassification code 10012812Term: Diffuse cutaneous mastocytosisEUCTR2006-006704-10-DEJADO Technologies GmbH